Advetorial

SYSTANE® PRO Preservative-Free

The ONLY Triple-Action Preservative-Free Formula That Provides Up to 12 Hours of Dry Eye Relief[1]*

Dr. François Piuze**

"For all the stresses and strains that life puts on our patients' eyes, TFOS DEWS III recommends the use of drops that enhance and/or stabilize the tear film, and these remain the cornerstone in managing dry eye. DEWS III also supports using dual-polymer formulations that contain both HP-guar and HA, which outperform other HA-based eye drops."‡‡‡

Dr. Christine Misener**

"Based on the TFOS Lifestyle Report, everyday factors such as weather, digital environment, cosmetics, and diet can negatively affect ocular health, and contribute to dry eye. To help support our patients' tear films and counter busy days that constantly burden their eyes, it's important to recommend a drop that's proven to provide long-lasting symptom relief."

**Dr. Piuze and Dr. Misener are paid consultants for Alcon.

Systane®'s Most Comprehensive, Long-Lasting Formula[2]

SYSTANE® PRO PF includes **the demulcent propylene glycol** to lubricate and soothe dry eyes[3] and is supported by the HP-guar meshwork, lipids, and hyaluronic acid. SYSTANE® PRO PF is suitable for **all types of dry eye**.[1]

All SYSTANE® Artificial Tears Use HP-GUAR

HP-guar and borate ions cross-link to form a gel-like structure in a pH-dependent mechanism[4,5†]:

- Mimics the tear film's mucin layer and enhances its thickness[6,7††]
- Acts as a "bandage" to support healing of corneal epithelial cell[4,5‡‡]
- Lowers tear osmolarity[7§§]



Forms a gel-like meshwork to support the demulcent[4,5†]

Optimizes the coverage area of phospholipids to reduce tear evaporation and enhance tear film stability[6‡]

Naturally occurring "moisture magnet" helps the lubricant provide long lasting hydration[7§]

Supporting the Demulcent

Statistically Significant Improvement in DES Score Following a Single Drop of SYSTANE® PRO PF in Each Eye (Day 1)[1]



After 30 days, patients also experienced[1]

- Statistically significant tear film stability improvement (NIBUT increase of 1.3 seconds vs. baseline, *P*<0.0001)***
- Clinically meaningful dry eye symptom-related quality of life improvement (IDEEL-SB decrease of 16.9 points vs. baseline, *P*<0.0001)†††

Phase 3, single-arm, open-label, multicentre study of subjects with dry eye disease (N=158)
SYSTANE® PRO PF: Day 1, 1 drop in each eye; Day 2 to 30, ≥1 drop in each eye 4x per day[1]

Recommend SYSTANE® PRO PF for Dry Eye Relief That Lasts Up to 12 hours[1]*

Takeaway 1

OTC artificial tears are a **cornerstone** of dry eye treatment. TFOS DEWS III (2025) emphasizes tailored, evidence-based management and formulations designed to stabilize the tear film and support ocular surface health.[8]

Takeaway 2

The unique formulation of SYSTANE® PRO PF includes a lubricant and several supporting polymers and lipids, for symptom relief in all types of dry eye.[1]

Takeaway 3

In a clinical trial, SYSTANE® PRO PF provided up to 12 hours of symptom relief on Day 1, and improved tear film stability and symptom-related quality of life over time.[1]

DES, Dry Eye Symptom; HA, Hyaluronic Acid; IDEEL-SB, Impact of Dry Eye on Everyday Life – Symptom Bother; NIBUT, noninvasive breakup time; PF, Preservative-Free.
*47% of patients experience meaningful symptom relief at 12 hours, N=153. Based on label claim or publicly available promotional materials.
†In vitro data.
‡In vitro data; Based on Systane Complete formulation.
§In vitro data; Corneal epithelium model; *P*<0.001.
††Animal model; Based on Systane Ultra formulation.
‡‡In vitro data; Based on Systane Original formulation.
§§Based on Systane Ultra formulation.
***8.474 seconds vs. 7.215 seconds at baseline. The mean change from baseline on Day 30 did not meet the established threshold for clinically meaningful change of 2.5 seconds.
†††30.75 vs. 47.62 points at baseline. IDEEL-SB is a validated questionnaire that measures symptom bother, quality of life, and treatment satisfaction. Clinically meaningful improvement in IDEEL-SB defined as ≥12-point reduction from baseline.
‡‡‡ "outperform" refers to 2x greater moisture retention (compared to HA-only formulation)

References: 1. Alcon data on file, 2025. **2.** Alcon data on file, 2024. **3.** FDA - OTC Ophthalmic Monograph M018: April 2022. **4.** Kesavan S, *et al. Macromolecules*. 1992;25:2026-2032. **5.** Ubels JL, *et al. Curr Eyes Res*. 2004;28:437-444. **6.** Moon SW, *et al. Cornea*. 2010;29:1430-1435. **7.** Ng A, *et al. Clin Ophthalmol*. 2018;12:695-700. 8. Jones L, et al. Am J Ophthalmol. 2025;279:289-386.

© 2026 Alcon Inc. CA-SAF-2600060

Alcon